Myriad Genetics Inc (MYGN)
Pretax margin
| Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -156,600 | -235,500 | -262,200 | -282,000 | -265,000 | -166,800 | -140,600 | -132,000 | -48,000 | -33,900 | -57,100 | -57,300 | -155,500 | -282,800 | -244,600 | -223,200 | -172,400 | -38,000 | -23,000 | 200 |
| Revenue (ttm) | US$ in thousands | 794,900 | 766,400 | 745,400 | 731,500 | 696,200 | 691,900 | 675,200 | 820,600 | 831,200 | 839,900 | 846,300 | 666,200 | 590,100 | 564,400 | 586,600 | 627,900 | 750,000 | 801,700 | 822,500 | 840,100 |
| Pretax margin | -19.70% | -30.73% | -35.18% | -38.55% | -38.06% | -24.11% | -20.82% | -16.09% | -5.77% | -4.04% | -6.75% | -8.60% | -26.35% | -50.11% | -41.70% | -35.55% | -22.99% | -4.74% | -2.80% | 0.02% |
June 30, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-156,600K ÷ $794,900K
= -19.70%
The pretax margin of Myriad Genetics Inc has exhibited fluctuations over the past several quarters, reflecting the company's ability to generate profits before accounting for taxes as a percentage of its total revenue.
The trend indicates a generally negative pretax margin, with values ranging from as low as -50.11% in Mar 31, 2021, to a slight positive of 0.02% in Dec 31, 2019. The company struggled with profitability, as shown by consistently negative values, particularly in recent quarters.
It is noteworthy that the pretax margin improved slightly in the most recent quarter, Jun 30, 2024, where it reached -19.70%, compared to the previous quarter's -30.73%. This improvement suggests efforts to enhance operational efficiency and cost management.
Further analysis and monitoring are necessary to determine if this positive trend will continue and if the company can sustain profitability in the long term. Additionally, comparing the pretax margin with industry benchmarks will provide better insights into Myriad Genetics Inc's performance relative to its peers.
Peer comparison
Jun 30, 2024